Matinas Biopharma Holdings Inc. (MTNB) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Matinas Biopharma Holdings Inc. (MTNB:NYSE), powered by AI.

Current Price
$0.72
Sector
Healthcare
What is the Matinas Biopharma Holdings Inc. stock price forecast?

Matinas Biopharma Holdings Inc. is currently trading at $0.72. View real-time AI analysis on Alpha Lenz.

What is Matinas Biopharma Holdings Inc. insider trading activity?

View the latest insider trading data for Matinas Biopharma Holdings Inc. on Alpha Lenz.

What is Matinas Biopharma Holdings Inc.'s P/E ratio?

View Matinas Biopharma Holdings Inc.'s valuation metrics on Alpha Lenz.

Matinas Biopharma Holdings Inc.

NYSE · MTNB
$0.72-0.03(-4.23%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Matinas Biopharma Holdings Inc.'s future dividend policy...
Alpha Chat Insight

Matinas Biopharma Holdings Inc.'s ROE is -166.6%. Explore profitability and growth together.

Ask for details

Company Overview

Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for unmet medical needs. Its primary function lies in the creation and advancement of lipid nano-crystal delivery technology, which aims to enhance the bioavailability and efficacy of pharmaceuticals. This company has a strategic focus on infectious diseases and rare disorders, addressing significant gaps in existing therapeutic options. Matinas Biopharma's innovative delivery platforms are designed to optimize drug exposure, enhance safety profiles, and enable oral dosing of complex molecules, which can potentially transform the treatment landscape. Operating within the biotechnology sector, the company impacts both healthcare and pharmaceutical industries by striving to improve the delivery and accessibility of treatments. By leveraging its proprietary technology, Matinas Biopharma plays a crucial role in the market by providing advanced solutions that could potentially reformulate how certain medications are administered, contributing to a broader goal of enhancing patient outcomes and quality of life.

CEOMr. Jerome D. Jabbour J.D.
SectorHealthcare
IndustryBiotechnology
Employees3

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
3Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-104.24%ROA
-166.59%ROE
-70.13%ROIC

Financial Health

$4.00MCash & Cash Equivalents
$-1.62MNet Debt
49.23%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Matinas Biopharma Holdings Inc. (ticker: MTNB) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 3 employees.

The current price is $0.72 with a P/E ratio of -x and P/B of -x.

ROE is -166.59%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Matinas Biopharma Holdings Inc. (MTNB) Stock Forecast 2026 $0.72 — Price, Financials & Analyst Targets | Alpha Lenz